Stockscreener 앱 받기
9.07
12.39%
1.00
시간 외 거래:
9.04
-0.03
-0.33%
전일 마감가:
$8.07
열려 있는:
$7.91
하루 거래량:
2.47M
Relative Volume:
0.82
시가총액:
$414.29M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-10.93
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
+14.81%
1개월 성능:
-10.82%
6개월 성능:
-35.63%
1년 성능:
+133.76%
1일 변동 폭
$7.91
$9.43
1주일 범위
$7.20
$9.43
52주 변동 폭
$3.709
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
9.07 | 353.78M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
Custom watchlist performance reports with Capricor Therapeutics Inc.Monthly Trade Result and Signal Summary - Newser
Analyzing drawdowns of Capricor Therapeutics Inc. with statistical toolsTrade Safety Matrix for Conservative Traders - Newser
What earnings revisions data tells us about Capricor Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
What does recent volatility data suggest for Capricor Therapeutics Inc.Long-Term Trend Tracking and Signal Summary - Newser
Why Capricor Therapeutics Inc. is moving todayVolume Spike Detection for Early Breakouts - Newser
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Class Action Filed Against Capricor Therapeutics, Inc. - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - The Malaysian Reserve
Capricor stock rises on FDA meeting for rejected drug (CAPR) - Seeking Alpha
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Capricor schedules FDA meeting on Duchenne therapy, delays earnings By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA | CAPR Stock News - GuruFocus
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Capricor Therapeutics Schedules FDA Meeting to Discuss Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA - GlobeNewswire
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional scanner results for Capricor Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - Barchart.com
What to expect from Capricor Therapeutics Inc. in the next 30 daysPredictive Model for Intraday Swing Forecast - Newser
Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm | FinancialContent - FinancialContent
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - cnhinews.com
Capricor Therapeutics Q2 Earnings: Latest Updates on DMD Drug Deramiocel Coming August 13 - Stock Titan
Capricor Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Popularity With Investors Under Threat As Stock Sinks 25% - 富途牛牛
Sector ETF performance correlation with Capricor Therapeutics Inc.Intraday Signal Forecast for Fast Traders - Newser
Investors in Capricor Therapeutics, Inc. Should Contact The - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER - GlobeNewswire
Capricor Shareholder Sues Board After FDA’s Heart Therapy Spurn - Bloomberg Law News
Investor Alert: Deadline Approaching to Join Capricor Therapeutics, Inc. (CAPR) Class ActionContact Levi & Korsinsky - Newsfile
The Gross Law Firm Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineCAPR - PR Newswire
What high frequency data says about Capricor Therapeutics Inc.Trend Following Ideas with Volume Confirmation - Newser
Will Capricor Therapeutics Inc. bounce back from current supportAI Volatility Forecast and Risk Monitor - Newser
‘Unprecedented’ FDA Leaks Sow Confusion For Patients, Sarepta and Capricor - BioSpace
ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor - GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure ... - Enidnews.com
Is it the right time to buy Capricor Therapeutics Inc. stockGet exclusive access to professional stock picks - Jammu Links News
When is Capricor Therapeutics Inc. stock expected to show significant growthUnmatched profit potential - Jammu Links News
Why is Capricor Therapeutics Inc. stock attracting strong analyst attentionRapidly growing investment returns - Jammu Links News
Capricor Therapeutics Inc. Stock Analysis and ForecastExceptional stock performance - Jammu Links News
Should I hold or sell Capricor Therapeutics Inc. stock in 2025Market-leading capital gains - Jammu Links News
Bank of New York Mellon Corp Has $832,000 Position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):